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ABSTRACT
Background. The Cancer and Leukemia Group B
(CALGB) conducted a phase II study evaluating
sunitinib in patients with progressive metastatic pan-
creas adenocarcinoma following prior gemcitabine-
based therapy (trial CALGB 80603; ClinicalTrials.gov
identifier, NCT00397787). The primary endpoint was to
determine the disease control rate (DCR) as measured
by the Response Evaluation Criteria in Solid Tumors
(complete response, partial response [PR], and stable
disease) at 6 weeks.
Patients and Methods. Patients aged >18 years with
an Eastern Cooperative Oncology Group (ECOG)
performance status score of 0 –2 and with progressive
pancreas adenocarcinoma following treatment with
gemcitabine were eligible. Sunitinib was dosed at 50
mg orally days 1–28, every 42 days (1 cycle). The sta-
tistical plan called for a three-stage design. A DCR
>15% was considered worthy of further study.
Results. In total, 77 patients were enrolled. Forty-two
(54.6%) enrollees were male. The median age was 65
years. The ECOG performance status score distribu-
tion was: 0, 39%; 1, 50%; 2, 11%. The DCR was 21.6%;
one patient (1.4%) had a PR and 15 patients (20.3%)
had stable disease as their best response. The progres-
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sion-free survival time was 1.31 months (95% confidence
interval [CI] 1.25–1.38 months) and overall survival time
was 3.68 months (95% CI, 3.06–4.24 months).
Conclusions. The study met its primary endpoint; how-
ever sunitinib had minimal activity and moderate toxicity
in a population of gemcitabine-refractory pancreas adeno-
carcinoma patients. For future studies, limiting enroll-
ment to patients with an ECOG performance status score
of 0–1 is recommended. The Oncologist 2010;15:
1310–1319
INTRODUCTION
Pancreas adenocarcinoma is a very challenging malignancy
because of its refractoriness to available treatments. About
42,000 people were estimated to have been diagnosed with
this disease in the U.S. in 2009, the substantial majority of
whom would have either locally advanced or metastatic
pancreas adenocarcinoma. These patients received either
gemcitabine or a gemcitabine-based combination as initial
therapy for locally advanced or metastatic disease [1, 2].
Most patients derive modest benefit from frontline therapy,
with a median time to progression of 2–4 months. About
half of all patients who receive frontline therapy are well
enough and eligible for second-line therapy [3, 4]. There is
not a standard second-line therapy for pancreas adenocar-
cinoma, nor a set of well-defined prognostic factors for sec-
ond-line therapy, and there is a relative dearth of trials
conducted in this disease setting [5]. Data from the random-
ized Charité Onkologie (CONKO)-003 trial and single-
institution data have suggested that a fluoropyrimidine
combined with oxaliplatin may represent a reasonable sec-
ond-line option [6–8]. Also, recent observations have dem-
onstrated that only a tiny fraction, approximately 2%, of
patients with pancreas adenocarcinoma who are potentially
eligible for a second-line therapy actually receive such ther-
apy in the context of a clinical trial [9]. This latter observa-
tion may be related to the limited availability of second-line
trials in this disease setting.
Sunitinib malate (SU11248, NSC #736511) is an orally
bioavailable, multitargeted small molecule inhibitor of sev-
eral receptor tyrosine kinases that are involved in tumor
proliferation and angiogenesis, including vascular endothe-
lial growth factor receptor (VEGFR)-1, VEGFR-2,
VEGFR-3, platelet-derived growth factor receptor, and
stem cell factor receptor (KIT) [10, 11]. VEGF and its re-
ceptors are over expressed in pancreas adenocarcinoma and
have been associated with the development of metastases
and a poor prognosis [12]. In part, the rationale for assess-
ing sunitinib in pancreas adenocarcinoma in this study re-
lates to the contribution of multiple signaling pathways to
the pathogenesis of this disease and the potential to impact
these pathways with a relatively broad-spectrum targeted
therapy along with, at the time, promising data from other
anti-VEGF inhibitors in this disease [13]. There is a prece-
dent for the development of novel targeted agents in pan-
creatic cancer [14]. Treatment with erlotinib combined with
gemcitabine has been shown to result in a longer time to tu-
mor progression and higher median and 1-year survival
rates than with gemcitabine alone in advanced pancreas
cancer [15]. Pancreatic adenocarcinoma is also character-
ized by a profound desmoplastic and stromal reaction that
has rarely been considered as a potential therapeutic target
[16, 17]. Sunitinib, via its broad inhibition of receptor ty-
rosine kinases, offers the potential to target both the tumor
directly and the stromal matrix. This paper reports a trial
performed by a National Cancer Institute (NCI)-funded co-
operative group evaluating the antitumor efficacy and




This phase II study was conducted by the Cancer and Leu-
kemia Group B (CALGB). Men and women aged 18
years with pancreas adenocarcinoma with histologic or cy-
tologic proof of malignancy and with evidence of disease
progression on a gemcitabine-containing frontline regimen
were eligible. Patients had to fall into one of the following
groups: (a) only one prior regimen of gemcitabine or a gem-
citabine-containing combination was to have been admin-
istered; (b) one prior combined chemoradiotherapy
regimen containing gemcitabine for inoperable locally ad-
vanced pancreas adenocarcinoma was permitted, as long as
the patient had subsequently progressed with measurable
disease outside the radiation port; (c) one prior adjuvant
gemcitabine-containing regimen or combined chemoradio-
therapy regimen containing gemcitabine could have been
administered, if the patient subsequently experienced pro-
gression of disease within 3 months of completion of adju-
vant therapy. Prior erlotinib was allowed. Measurable,
metastatic disease was required (20 mm by conventional
computerized tomography [CT] or 10 mm by spiral CT);
locally advanced pancreatic cancer with the primary tumor
as the sole site of disease was not allowed. An Eastern Co-
operative Oncology Group (ECOG) performance status
score of 0–2 was required. Required initial laboratory cri-
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teria included the following: absolute neutrophil count
1,500/ul, platelet count 100,000/l, bilirubin 1.5 mg/
dl, prothrombin time and partial thromboplastin time
1.5 the upper limit of normal (ULN), serum creatinine
1.5 mg/dl, and aspartate aminotransferase 2.5 ULN if
no liver metastases r 5 ULN if liver metastases were
present. Written informed consent was required and the
protocol was reviewed and approved by the local institu-
tional review board at each participating site.
Exclusion criteria included the following. No prior ther-
apy with any other antiangiogenic agent (e.g., bevaci-
zumab, sorafenib, etc.) was permitted. No significant
cardiac disease was permitted; specifically, the QTc inter-
val had to be 500 msec. No prior myocardial infarction,
cardiac arrhythmia, active angina, active congestive cardiac
failure (New York Heart Association class III or class IV),
or coronary artery bypass grafting or stenting in the previ-
ous 12 months prior to registration was allowed. No history
of a cerebrovascular accident or transient ischemic attack
within 12 months or pulmonary emboli within 6 months
prior to registration was allowed. Patients with a nonheal-
ing wound, ulcer, or bone fracture were not enrolled. No
history of significant bleeding (within 6 months), abdomi-
nal fistula, gastrointestinal perforation, or intra-abdominal
abscess was permitted. Patients with duodenal invasion by
tumor on CT were not enrolled. Inhibitors and inducers of
cytochrome P450 3A4 had to be discontinued prior to and
during treatment with sunitinib. Also, drugs with proar-
rhythmic potential were not allowed during the study. Use
of warfarin anticoagulants was not allowed. No “currently
active” second malignancy, other than nonmelanoma skin
cancer, was permissible. Patients were not considered to
have a “currently active” malignancy if they had completed
therapy and were considered by their physician to have a
30% risk for relapse. Brain metastases excluded patients
from enrollment.
Study Procedures
Prior to registration, patients underwent a history and phys-
ical examination including notation of height, weight,
ECOG performance status score, vital signs (blood pres-
sure, temperature, pulse, respiration), and a pregnancy test
for all females of child-bearing potential. A baseline CT or
magnetic resonance imaging scan documenting all sites of
metastatic disease was required within 4 weeks of study en-
rollment. A baseline electrocardiogram and either echocar-
diogram (ECHO) or multigated acquisition (MUGA) scan
were performed prior to the initiation of therapy. Patients
were evaluated weekly for toxicity and blood pressure mon-
itoring during the first cycle. Tumor restaging was per-
formed every cycle (every 6 weeks) for each of the first four
cycles and then every other cycle thereafter. A follow up
ECHO or MUGA scan was performed after the second cy-
cle of therapy (every 12 weeks). Treatment was continued
indefinitely until either disease progression or unacceptable
toxicity occurred.
As part of the quality assurance program of the CALGB,
members of the audit committee visit all participating insti-
tutions at least once every 3 years to review source docu-
ments. The auditors verify compliance with federal
regulations and protocol requirements, including those per-
taining to eligibility, treatment, adverse events, tumor re-
sponse, and outcome in a sample of protocols at each
institution. Such on-site review of medical records was per-
formed for a subgroup of 11 patients (14%) of the 77 pa-
tients under this study.
Treatment and Dose Adjustments
Sunitinib malate was provided by the Division of Cancer
Treatment and Diagnosis (DCTD), NCI, under a collabora-
tive agreement between Pfizer and the DCTD. The starting
dose of sunitinib was 50 mg. Sunitinib was dosed at 50 mg
orally daily irrespective of timing of food, for days 1–28
followed by 14 days of rest, constituting one treatment cy-
cle (42 days, 6 weeks). Dose level 1 of sunitinib was 37.5
mg and level 2 was 25 mg. No dose re-escalation was per-
mitted following dose adjustment for toxicity. Patients re-
quiring dose reduction beyond the 2 level were to
discontinue protocol therapy. A treatment break of up to 4
weeks was permitted for toxicity or other disease-related
complications. Protocol-specific dose modifications were
prescribed for grade 3 or 4 hematologic toxicity (neutrope-
nia, thrombocytopenia), grade 3 or 4 fatigue, hypertension,
QTc prolongation, decreases in left ventricular ejection
fraction, and grade 3 or 4 skin toxicity or grade 3 or 4 bleed-
ing. For all other grade 3 toxicities, sunitinib was held until
toxicity improved to grade 2. For other grade 4 toxicities,
protocol therapy was permanently discontinued.
Statistical Plan and Analysis
The study was designed as a single-arm, nonrandomized,
multicenter cooperative group (CALGB) phase II trial of
single-agent sunitinib for previously treated pancreas ade-
nocarcinoma in patients with measurable metastatic dis-
ease. The primary endpoint of the study was disease the
control rate (DCR), specified as either a complete response
(CR), partial response (PR), or stable disease (SD) as mea-
sured by the Response Evaluation Criteria in Solid Tumors
(RECIST) 6 weeks following the initiation of protocol ther-
apy [18, 19]. The null hypothesis that the DCR according to
the RECIST was 5%, versus the alternative that the DCR
was 15%, was tested using a three-stage design. If the
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DCR was 15%, then single-agent sunitinib was to be con-
sidered worthy of further study in gemcitabine-refractory
pancreas adenocarcinoma. Nineteen patients were to be en-
tered in stage 1. If a DCR of 0% was observed during the
first 19 patients studied, the trial was to be closed because of
a lack of efficacy. If a DCR 5% was observed among the
first 19 patients studied, 20 additional patients were to be
enrolled in stage 2. If a DCR 2% was observed among the
first 39 patients studied, the trial was to close at stage 2 be-
cause of a lack of efficacy. If two or more cases of a CR, PR,
or SD (DCR 5%) were observed among the first 39 pa-
tients studied, 21 additional patients were to be enrolled in
stage 3. Sunitinib was to be considered worthy of further
investigation at stage 3 if six cases of CR, PR, or SD (DCR
of 10%) were observed among 60 eligible patients treated.
The simulated power and significance level under this de-
sign (10,000 simulations) are 0.9 and 0.08, respectively.
The sample size was increased to 64 to allow for replace-
ment of patients who did not initiate protocol therapy. All
patients who met the eligibility criteria and received at least
one dose of protocol therapy were included in the analysis
of the primary endpoint.
The secondary endpoints of the study were: response
duration, progression-free survival (PFS), toxicity, and
overall survival. Duration of response was determined for
the subset of patients who achieved a confirmed response
(CR or PR). Duration of an objective response was defined
as the time from the first tumor assessment indicating re-
sponse to the time of disease progression or death from any
cause. PFS and overall survival times were assessed using
the Kaplan–Meier method. Toxicity data were graded using
the NCI Common Toxicity Criteria for Adverse Events,
version 3.0. Particular attention was paid to hypertension,
cardiac events, bleeding, and thrombotic events. All ad-
verse events were reported to the CALGB. All patients who




Patient registration and data collection were managed by
the CALGB Statistical Center. Data quality was ensured by
careful review of data by CALGB Statistical Center staff
and by the study chairperson (E.O.’R.). Statistical analyses
were performed by CALGB statisticians.
In total, 77 patients were enrolled from November 2006
through November 2007. The study met the criteria for pro-
ceeding to the third stage. Enrollment to the study was very
brisk in the last several weeks and hence, in view of com-
mitment to multiple study sites, the study recruitment ex-
ceeded the goal of 64 patients. Forty-two patients (54.5%)
were male. The median age was 65 years (range, 42– 87
years). The ECOG performance status score was 0 in 30 pa-
tients (38.9%), 1 in 38 patients (49.4%), and 2 in nine pa-
tients (11.7%). Eight-four percent of patients had liver
metastases on entry to the study. Thirty-six percent of pa-
tients had had stable disease to prior gemcitabine and
10.4% had experienced a response to gemcitabine therapy.
A detailed summary of patient characteristics is provided in
Table 1.
Primary Endpoint
Seventy-four patients were eligible for analysis of the pri-
mary study endpoint. Three of the 77 patients enrolled
never received treatment. The median follow-up time was
22.1 months. The median number of cycles delivered
was one. The (CR, PR, or SD by the RECIST at 6 weeks)
was 21.6%, with one patient (1.4%) with a PR and 15 pa-
tients (20.3%) with SD. Forty patients (54%) had progres-
sive disease as their best response. Eighteen patients
(24.3%) did not have a follow-up scan and were not evalu-
able for the primary endpoint. Those patients ended treat-
ment prior to completing one cycle of therapy as a result of
progressive disease (n  3), death resulting from progres-
sive disease (n  9), and withdrawal of consent prior to re-
ceiving any treatment (n  3). Only one of those patients
was reported to have gone on to receive further treatment.
For the patient with an observed PR, this was maintained
for 16 weeks. For the 15 patients who had SD as their best
response, the median SD duration was 11.3 weeks (range,
5.7–55 weeks). Response data are summarized in Table 2.
Secondary Endpoints
Seventy-four patients were eligible for the survival analy-
sis. The median duration of protocol therapy was 28 days
(range, 2–126 days). The median PFS interval for all 74 pa-
tients was 1.31 months (95% confidence interval [CI],
1.25–1.38 months) (Fig. 1). Seventy-three patients had died
and one was alive at the time of the final study analysis. The
overall median survival duration was 3.68 months (95% CI,
3.06–4.24 months) (Fig. 2).
Toxicity
All 74 patients who received any dose of study drug were
eligible for toxicity assessment. Twenty-one (27.1%) pa-
tients required a dose modification during cycle 1. The prin-
cipal grade 3–5 toxicities observed were hematologic (n 
16, 21.7%, and nonhematologic (n  32, 43.2%). Specifi-
cally, relevant grade 3 toxicities included: hypertension in
three patients (4%), fatigue in 13 patients (17.6%), bleeding
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in five patients (6.8%), thrombotic microangiopathy/renal
failure in two patients (2.7%), and thrombosis in two pa-
tients (2.7%). There were two (2.7%) grade 5 events on
study, a gastrointestinal perforation and respiratory dis-
tress. Both of these grade 5 toxicities were attributed to the
study drug and related to progression of underlying pan-
creas adenocarcinoma. The commonest reasons for study
discontinuation were progression of disease (POD) during
therapy (61%), adverse event (9.1%), death during treat-
ment/POD (14.3%), or declining further treatment (9.1%).
Toxicity information is summarized in Table 3.
DISCUSSION
Progressive metastatic pancreas adenocarcinoma following
frontline gemcitabine-based therapy represents a very poor
prognostic disease setting with median survival times mea-
sured in the several month range [20, 21]. However, this pa-
tient group represents a significant patient number in that
about 40%–60% of patients who receive frontline therapy
are well enough and eligible to receive further therapy [4].
New therapies are desperately needed for this patient pop-
ulation. This study assessed the single-agent utility of
sunitinib, a broad-spectrum receptor tyrosine kinase inhib-
itor, in this patient population in the context of a large, co-
operative group, single-arm, phase II clinical trial.
Sunitinib represents an attractive drug to assess given its in-
hibition of multiple targets and the importance of the VEGF
pathway in pancreas adenocarcinoma [12, 22] and, notwith-
standing, potential activity against the desmoplastic stro-
mal matrix, which appears to be fundamental to the
development and maintenance of the pancreatic neoplastic
phenotype [23]. This study technically met its primary end-
point of disease control in that 21.7% of patients had a CR,
PR, or SD at 6 weeks (mostly SD). However, the very short
time on study of less than one treatment cycle, reflected in










Median age (range), yrs 65 (42–87)





Pancreas/primary bed 50 (64.9%)
Liver 65 (84.4%)
Lung 23 (29.9%)










Gemcitabine  tyrosine kinase inhibitor
(erlotinib)
12 (15.6%)
(Chemo)radiation therapy 19 (24.7%)
Experimental therapy with or without
gemcitabine
4 (5.2%)
Best response to prior gemcitabine
therapyc
Complete response 2 (2.6%)
Partial response 6 (7.8%)
Stable disease 28 (36.4%)
Progression of disease 38 (49.4%)
Unknown response 3 (3.9%)
Prior therapy context
Adjuvant therapy 5 (6.5%)
Locally advanced disease 5 (6.5%)
Metastatic disease 67 (87%)
Months from initial diagnosis to start of
protocol therapy, median (range)
8 (2.8–80)
Weeks from prior therapy to start of
protocol therapy, median (range)
5 (2.9–31) wks
aOther sites include lymph nodes, ascites,
retroperitoneum, spleen.
bPrior surgery included prior definitive resection,
exploratory laparotomy, and surgical bypass.
cAs reported by investigator.
Abbreviation: ECOG, Eastern Cooperative Oncology
Group.
Table 2. Response data (n  74)
Characteristic n (%)
Primary endpoint: disease control
rate at 6 wks (CR, PR, SD)
16 (21.6%)
Response 6 wks after starting therapy
PR 1 (1.4%)
SDa 15 (20.3%)
Progressive disease 40 (54%)
Insufficient evaluation 18 (24.3%)
aOne patient had an insufficient response evaluation at 6
weeks, but the best overall response was SD and the
patient subsequently progressed after 1 year on study.
Abbreviations: CR, complete response; PR, partial
response; SD, stable disease.
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the short PFS time of 1.31 months, the moderate toxicity,
and the limited survival argue against any usefulness of
sunitinib in this patient population. The experience and re-
sults observed in this study have been mirrored by other tri-
als conducted with other targeted agents in a similar
treatment population [20, 24–27]. One positive note was
the interest in this trial evident in its very brisk recruitment,
suggesting that a cooperative group can provide a good fo-
rum for conducting second-line clinical trials with novel
agents in patients with previously treated pancreas adeno-
carcinoma.
Since the time of study conception, notwithstanding the
Figure 1. PFS in patients treated with sunitinib in the setting of prior gemcitabine treatment for metastatic pancreas adenocar-
cinoma.
Abbreviations: CI, confidence interval; PFS, progression-free survival.
Figure 2. OS in patients treated with sunitinib in the setting of prior gemcitabine treatment for metastatic pancreas adenocarci-
noma.
Abbreviations: CI, confidence interval; OS, overall survival.
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Table 3. Toxicity data (n  74)
Adverse event Grade 3, n (%) Grade 4, n (%) Grade 5, n (%)
Hematologic
Hemoglobin 4 (5.4%) – –
Neutrophils 5 (6.8%) – –
Platelets 6 (8.1%) 1 (1.4%) –
Cardiovascular
Hypertension 3 (4%) – –
Constitutional
Fatigue 13 (17.6%) 1 (1/4%) –
GI
Anorexia 1 (1.4%) – –
Dehydration 5 (6.8%) – –
Diarrhea 2 (2.7%) – –
Constipation 2 (2.7%) – –
Bloating 2 (2.7%)
Stomatitis 1 (1.4%) – –
Nausea 7 (9.5%) – –
Vomiting 5 (6.8%) – –
GI obstruction 1 (1.4%) – –
GI perforation – – 1 (1.4%)
GI stricture 1 (1.4%) – –
Hemorrhage
Respiratory 1 (1.4%) – –
GI 4 (5.4%) – –
Infection
Febrile neutropenia 2 (2.7%) – –
Fever and grade 1–2 ANC 4 (5.4%) – –
Other 3(4.1 %) – –
Metabolic/laboratory
AST/ALT 5 (6.8%) – –
Bilirubin 3 (4.1%) 1 (1.4%)
Hypercalcemia 1 (1.4%)
Hypocalcemia 2 (2.7%) – –
Hypoglycemia 1 (1.4%) – –
Hypokalemia 2 (2.7%) – –
Hyponatremia 3 (4.1%) 1 (1.4%) –
Hypernatremia 1 (1.4%) – –
Prolonged PT 2 (2.7%) – –
Neurologic
Confusion 2 (2.7%) – –
Dizziness 1 (1.4% – –
Muscle weakness 2 (2.7%) – –
Pain 9 (12.2%) 1 (1.4%) –
Pulmonary
Dyspnea 3 (4.1%) – 1 (1.4%)
Renal
Thrombotic microangiopathy 1 (1.4) – –
Renal failure 1 (1.4) – –
GU stricture 1 (1.4%) – –
Vascular
Thrombosis/embolism 2 (2.7%) 1 (1.4%) –
Toxicity information pertains to all causes.
Abbreviations: ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; GI,
gastrointestinal; GU, genitourinary; PT, prothrombin time.
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strong preclinical rationale for antivascular therapy in pan-
creas adenocarcinoma [12, 22, 28], the accumulating clini-
cal data speak against the utility of targeting VEGFR
pathways as being a useful clinical approach. In the treat-
ment of frontline advanced pancreas adenocarcinoma, there
are now two fully reported randomized trials that have
failed to meet a primary survival endpoint of demonstrating
superiority for the addition of the antivascular agent [29–
34], and two other studies evaluating the addition of ax-
itinib to gemcitabine and the addition of aflibercept
(VEGF-Trap) to gemcitabine have been preliminarily re-
ported as not meeting a survival endpoint. The reasons for
the failure of antivascular therapy remain relatively poorly
understood and may relate to the hypoxic microenviron-
ment of pancreas adenocarcinoma, along with drug deliv-
ery and distribution challenges [17, 35].
Targeted agents have been extensively assessed in both
the first- and second-line setting in pancreas adenocarci-
noma. Using single or combination targeted agents in a sec-
ond-line setting has yielded rare responses, short PFS and
overall survival times, and limited value to this strategy
(Table 4). Drugs assessed include erlotinib [25], saracatinib
[24], everolimus [26], bevacizumab plus erlotinib [20], and
sunitinib. Somewhat more activity has been observed for
combining a targeted agent with cytotoxic therapy in the re-
fractory disease setting [36], although here the benefit may
relate to the cytotoxic backbone alone because no random-
ized trials have evaluated the addition of a targeted agent in
the second-line setting when combined with cytotoxic ther-
apy.
Where do we go from here in the second-line treatment
of pancreas adenocarcinoma? Treating patients with ad-
vanced pancreas cancer refractory to frontline therapy re-
mains very challenging. Of fundamental importance is the
patient’s functional status at the time of second-line treat-
ment initiation [5, 30]. Arguably, performance status may
be one of the key predictors of outcome in the second-line
setting of treatment for pancreas adenocarcinoma, along
with whether or not patients responded to initial gemcitab-
ine-based therapy. The latter characteristic was not for-
mally assessed as part of this particular study, but was
provided by the investigator. In the trial reported herein, re-
sponse to prior therapy did not appear to correlate with out-
come; however, other cytotoxic-based trials have stratified
for response to frontline therapy [21]. In another retrospec-
tive analysis, the first-line PFS interval was identified to be
the main prognostic factor for benefit from second-line
therapy [3]. The current study permitted patients with an
ECOG performance status score of 2. In reality, these pa-
tients probably never really had a chance to benefit from
second-line therapy because their disease-related complica-
tions/comorbidities were always likely to overwhelm the
potential benefit of the therapeutic agent under study. Re-
stricting enrollment in this second-line setting to patients
with an ECOG performance status score of 0–1 is recom-
mended going forward, particularly in studies accrued from
a broad base spanning academic centers through commu-
nity practice settings.
Regardless, the fundamental challenge for making
progress in the treatment of pancreas adenocarcinoma, irre-
spective of disease setting, does not relate to patient selec-
tion. It relates to the dearth of truly active drugs with
meaningful impacts on pathways that are important for
maintenance and progression of the malignant metastatic
state and the natural history of the disease. In these authors’
opinions, cytotoxic therapy remains entrenched as part of
Table 4. Selected phase II trials of second-line therapy for pancreas adenocarincoma using targeted agents
Therapy n RR Median survival Study
Bevacizumab  erlotinib 36 2.7% 102 days (3.4 mos) Ko et al. [20]
Capecitabine  erlotinib 30 11% 6.7 mos Kulke et al. [36]
Erlotinib 18 NR 3.1 mos Iyer et al. [25]
Saracatinib 19 NR 2.5 mos Messersmith et al. [24]
5-Fluorouracil  celecoxib 17 11.7% 15 weeks (3.5 mos) Milella et al. [39]
Capecitabine  celecoxiba 35 9% 19 weeks (4.4 mos) Pino et al. [40]
Nab-paclitaxel 20 5% 7.3 mos Hosein et al. [41]
Gemcitabine  oxaliplatin  imatinib
(phase I)
26 7.7% 5.7 mos Starling et al. [42]
Everolimus (RAD001) 33 0% 4.5 mos Wolpin et al. [26]
Sunitinib 77 1.4% 3.68 mos O’Reilly et al. [present study]
aIncluded patients with pancreas and biliary malignancies.
Abbreviations: NR, not reported; RR, response rate.
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the treatment of pancreas cancer either first- or second-line.
Conroy et al. [37] recently reported preliminary results
from the Partenariat de Recherche Oncologie Digestive
(PRODIGE) 4/ACCORD 11 trial demonstrating clear su-
periority for 5-fluorouracil, leucovorin, irinotecan, and ox-
aliplatin (the FOLFIRINOX regimen) over gemcitabine in
patients with untreated metastatic pancreas cancer. This
signal deserves further evaluation, and indeed, variants of it
(infusional 5-fluorouracil and oxaliplatin [6, 21, 38]) are al-
ready established as a second-line treatment. For now, the
role of targeted agents in previously treated pancreas cancer
patients appears to be with integration with cytotoxic ther-
apy. Olive and colleagues elegantly demonstrated that inhi-
bition of Hedgehog signaling in a pancreas cancer mouse
model refractory to gemcitabine may enhance drug delivery
and effect short-term disease stabilization in the presence of
IPI-926, a hedgehog signaling inhibitor [35]. If the proof of
principle of this strategy holds, the implications could be
significant for the treatment of pancreas adenocarcinoma.
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